Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 49Carcinoma, Renal Cell 30Neoplasm Metastasis 18Neoplasms 15Kidney Neoplasms 14Neuroendocrine Tumors 11Carcinoma, Neuroendocrine 9Prostatic Neoplasms 7Melanoma 7Triple Negative Breast Neoplasms 6Thyroid Neoplasms 6Sarcoma 6Meningioma 6Lymphoma 6Glioma 6Endometrial Neoplasms 6Tuberous Sclerosis 5Stomach Neoplasms 5Recurrence 5Lymphoma, Mantle-Cell 5Head and Neck Neoplasms 5Colorectal Neoplasms 5Carcinoma, Hepatocellular 5Carcinoma 5Pancreatic Neoplasms 4Ovarian Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Liver Neoplasms 4Carcinoma, Islet Cell 4Astrocytoma 4

Interventions

pembrolizumab 4Docetaxel 3Cisplatin 3Cetuximab 3Gefitinib 2Cyclophosphamide 2zalutumumab 1fludarabine phosphate 1fludarabine 1durvalumab 1atezolizumab 1advexin 1abemaciclib 1Vorinostat 1Radiotherapy 1Radiosurgery 1Oxaliplatin 1Nivolumab 1Imatinib Mesylate 1Everolimus 1Erlotinib Hydrochloride 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms, Squamous Cell × Everolimus × Clear all
NCT01111058 2020-04-07

Everolimus Versus Placebo in Head and Neck Cancer

University of Chicago

Phase 2 Terminated
52 enrolled 13 charts
Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡